Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
The New England Journal of Medicine
|
January 20, 2006
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
Kathleen M Schmeler, Henry T Lynch, Lee-may Chen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Gynecologic Oncology
|
June 2, 2026
Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98]
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
David S Hong, Nicole Concin, Ignace Vergote, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
The New England Journal of Medicine
|
January 20, 2006
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
Kathleen M Schmeler, Henry T Lynch, Lee-may Chen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Gynecologic Oncology
|
June 2, 2026
Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98]
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
David S Hong, Nicole Concin, Ignace Vergote, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Page
of 11